SBTX - Ticker AI Digest

SkinBioTherapeutics PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (SBTX) 1
SBTX 06:01
SkinBioTherapeutics PLC
Croda Commercial Launch Progressing as Expected
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Here is a summary of the news article
SkinBioTherapeutics plc, a life science company focused on skin health, announces that the commercial launch of ZenakineTM by Croda Beauty is progressing as expected. ZenakineTM is a neuroactive ingredient designed to counteract the effects of stress on the skin and improve overall well-being by enhancing melatonin production and improving sleep quality. The company has a long-standing commercial and manufacturing agreement with Croda plc, and due to the competitiveness of the industry, SkinBioTherapeutics is under a strict confidentiality agreement regarding sales and market forecast information. The company also announces an upcoming investor presentation on July 3, 2025, regarding a recently signed commercial agreement with Superdrug. SkinBioTherapeutics is a consolidator in the skin health market, making acquisitions in complementary areas and expanding its distribution, geographical reach, and manufacturing capabilities. The companys proprietary platform, SkinBiotix®, is based on discoveries made by the translational dermatology team at the University of Manchester.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
SBTX 06:01
SkinBioTherapeutics PLC
Croda Commercial Launch Progressing as Expected
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Here is a summary of the news article
SkinBioTherapeutics plc, a life science company focused on skin health, announces that the commercial launch of ZenakineTM by Croda Beauty is progressing as expected. ZenakineTM is a neuroactive ingredient designed to counteract the effects of stress on the skin and improve overall well-being by enhancing melatonin production and improving sleep quality. The company has a long-standing commercial and manufacturing agreement with Croda plc, and due to the competitiveness of the industry, SkinBioTherapeutics is under a strict confidentiality agreement regarding sales and market forecast information. The company also announces an upcoming investor presentation on July 3, 2025, regarding a recently signed commercial agreement with Superdrug. SkinBioTherapeutics is a consolidator in the skin health market, making acquisitions in complementary areas and expanding its distribution, geographical reach, and manufacturing capabilities. The companys proprietary platform, SkinBiotix®, is based on discoveries made by the translational dermatology team at the University of Manchester.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 3
SBTX 06:01
SkinBioTherapeutics PLC
Result of WRAP Retail Offer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
SkinBioTherapeutics plc, a life science group focused on skin health, announces the results of its recent fundraise at an issue price of 17 pence per share. The company has raised approximately £0.1 million through the WRAP Retail Offer, in addition to the previously announced Placing and Subscription. In total, the company has raised gross proceeds of £4.2 million and will issue 587,191 new Ordinary Shares at the Issue Price. Admission of the new shares is expected to take place on or around June 24, 2025, bringing the total issued ordinary share capital to 258,779,463 Ordinary Shares. The company also announces an investor presentation for shareholders via the Investor Meet Company platform in the week commencing June 30, 2025.
SBTX 13:03
SkinBioTherapeutics PLC
WRAP Retail Offer
SBTX 06:01
SkinBioTherapeutics PLC
Superdrug agreement, Placing & Retail Offer
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
SBTX 10:29
SkinBioTherapeutics PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
SBTX 06:01
SkinBioTherapeutics PLC
Croda Commercial Launch Progressing as Expected
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Here is a summary of the news article
SkinBioTherapeutics plc, a life science company focused on skin health, announces that the commercial launch of ZenakineTM by Croda Beauty is progressing as expected. ZenakineTM is a neuroactive ingredient designed to counteract the effects of stress on the skin and improve overall well-being by enhancing melatonin production and improving sleep quality. The company has a long-standing commercial and manufacturing agreement with Croda plc, and due to the competitiveness of the industry, SkinBioTherapeutics is under a strict confidentiality agreement regarding sales and market forecast information. The company also announces an upcoming investor presentation on July 3, 2025, regarding a recently signed commercial agreement with Superdrug. SkinBioTherapeutics is a consolidator in the skin health market, making acquisitions in complementary areas and expanding its distribution, geographical reach, and manufacturing capabilities. The companys proprietary platform, SkinBiotix®, is based on discoveries made by the translational dermatology team at the University of Manchester.
SBTX 06:01
SkinBioTherapeutics PLC
Notice of IMC Shareholder Presentation
SBTX 10:29
SkinBioTherapeutics PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
SBTX 06:01
SkinBioTherapeutics PLC
Result of WRAP Retail Offer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
SkinBioTherapeutics plc, a life science group focused on skin health, announces the results of its recent fundraise at an issue price of 17 pence per share. The company has raised approximately £0.1 million through the WRAP Retail Offer, in addition to the previously announced Placing and Subscription. In total, the company has raised gross proceeds of £4.2 million and will issue 587,191 new Ordinary Shares at the Issue Price. Admission of the new shares is expected to take place on or around June 24, 2025, bringing the total issued ordinary share capital to 258,779,463 Ordinary Shares. The company also announces an investor presentation for shareholders via the Investor Meet Company platform in the week commencing June 30, 2025.
SBTX 13:03
SkinBioTherapeutics PLC
WRAP Retail Offer
SBTX 06:01
SkinBioTherapeutics PLC
Superdrug agreement, Placing & Retail Offer

AI Crunch

Single-Ticker AI Crunch
SBTX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for SkinBioTherapeutics PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full SBTX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for SBTX on 2025-06-30.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
25268946
Enterprise Value
36952896
Public Float
60.21
Broker Target
29
Shares Out
259168671
Long Interest
92
Short Interest
8
Exchange
LSE
Currency Code
GBX
ISIN
GB00BF33H870
Market
LSE - AIM
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-24
Net Debt
-3785967.0
Cash
4779433.0
EPS
-
Net Income
-696253.0
Revenue
4638147.0
Enterprise Value
36952896
Trailing PE
-
Forward PE
-
Price Sales TTM
5.4481
Price Book MRQ
2.6827
EV Revenue
4.6318
EV EBITDA
-8.0802

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
28.57
Institutions As Of
2026-01-15
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
15
Sale TR1
8
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit SBTX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-06-30 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
SkinBioTherapeutics PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
SBTX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-06-30 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 19.70%
RSI Gauge
Price Change
AI Forecast